Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
11/2003
11/18/2003US6649607 Compositions and methods for treating or preventing convulsions or seizures
11/18/2003US6649604 Analgesics; antidiabetic agents; antiinflamamtory agents
11/18/2003US6649600 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics
11/18/2003US6649179 A plasminogen activator inhibitor comprising zinc oxide which adsorbs a plasminogen activator and inhibits its activity, thus improving rough skin
11/18/2003US6649172 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants
11/18/2003US6649168 Pharmaceutical compositions comprising TGF-beta
11/18/2003US6649145 Wound healing, treating infections
11/18/2003CA2143845C Self-assembling recombinant papillomavirus capsid proteins
11/13/2003WO2003093465A1 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
11/13/2003WO2003093409A2 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003WO2003093297A2 Protein kinase modulators and methods of use
11/13/2003WO2003093257A1 Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentaidenoic acid derivatives having selective activity for retinoid x (rxr) receptors
11/13/2003WO2003093249A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093245A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003WO2003093243A1 Preparations for the topical application of anti-androgenically active substances
11/13/2003WO2003093237A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
11/13/2003WO2003092761A1 Surgical material comprising water glass fibres
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092706A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003WO2003092703A1 Methods and compositions for inhibition or irritation by disaccharide and metal ions
11/13/2003WO2003092697A1 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092668A1 Use of agmatine for topical application
11/13/2003WO2003092667A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003WO2003092664A1 Micro-capsules with anti-acne active ingredients
11/13/2003WO2003092647A2 Transport system in biological systems
11/13/2003WO2003092641A1 Topical glycopyrrolate product
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092595A2 Tyrosine kinase inhibitors
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003082864A3 Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003066001A3 Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
11/13/2003WO2003064447A3 Immune-modulating peptide
11/13/2003WO2003042113A8 Production of cell suspensions
11/13/2003WO2003039444A3 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003022871A3 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
11/13/2003WO2003017939A3 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
11/13/2003WO2003017917A3 Use of microbiology non-viral substances for treating acne
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003009820B1 Methods for promotion of hair growth comprising topical application of prostaglandin analogues
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002066648A3 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
11/13/2003WO2002050030A8 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
11/13/2003WO2002050029A8 Tetracyclic derivatives as spla2 inhibitors
11/13/2003WO2002030443A9 Regulation of human skin healing
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212269 Kinase inhibitor; antitumor agents, psoriasis, skin disorders, antiarthritic agents
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212129 System and method for revitalizing human skin
11/13/2003US20030212125 Topical applying; skin disorders; antiinflammatory agents
11/13/2003US20030212093 Imidazonaphthyridines
11/13/2003US20030212091 Aryl ether substituted imidazoquinolines
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212068 Antiinflammatory agents; antiallergens; antiarthritic agents
11/13/2003US20030212057 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
11/13/2003US20030212055 Cinnoline compounds
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212024 Compositions and methods for cell dedifferentiation and tissue regeneration
11/13/2003US20030211993 Control cell proliferation, cell differentiation; culture product
11/13/2003US20030211986 Protein a compositions and methods of use
11/13/2003US20030211969 Administering activated protein c; controlling blood coagulation
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211170 Wound healing agents
11/13/2003US20030211165 Anticancer agents; mixture of hydrophilic, crosslinked polymer and drugs
11/13/2003US20030211134 Topical glycopyrrolate product
11/13/2003US20030211106 Binding tumor necrosis factor to antibody
11/13/2003US20030211103 Use of primate IFN-gamma binding molecules
11/13/2003US20030211101 Vascular endothelial growth factor-like protein from ORF viruses binds and activates mammalian VEGF receptor-2, and uses thereof
11/13/2003CA2749172A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2487693A1 Method for producing preparations rich in tocotrienol
11/13/2003CA2484599A1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003CA2484597A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003CA2484551A1 Smart pro-drugs of serine protease inhibitors
11/13/2003CA2484312A1 Catechin multimers as therapeutic drug delivery agents
11/13/2003CA2484209A1 Protein kinase modulators and methods of use
11/13/2003CA2484189A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003CA2484173A1 4-azasteroid derivatives as androgen receptor modulators
11/13/2003CA2484065A1 Inhibitors of histone deacetylase
11/13/2003CA2484024A1 Surgical material comprising water soluble glass fibres
11/13/2003CA2483996A1 Promoters exhibiting endothelial cell specificity and methods of using same
1 ... 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 ... 1065